This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents-have been ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...